Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00988429 · ClinicalTrials.gov registry record · Phase 3
Efficacy and Safety of Eslicarbazepine Acetate (BIA 2-093) as Adjunctive Therapy for Refractory Partial Seizures
A Phase 3 study of Partial Epilepsy, sponsored by Bial - Portela C S.A..
- Completed
- Registry status
- Phase 3
- Development phase
- 653
- Enrollment target
- 20
- Study locations
NCT00988429 is a Phase 3 study of Partial Epilepsy that has completed, run by Bial - Portela C S.A.. The registered enrollment target is 653 participants, above the 427-participant average among 7 other Partial Epilepsy trials with a reported enrollment target (53% higher). The trial reports 20 study locations across 6 states.
The verdict
NCT00988429, a Phase 3 study of Partial Epilepsy, has completed, sponsored by Bial - Portela C S.A..
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 653 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to determine whether Eslicarbazepine acetate (BIA 2-093) is an effective adjunct therapy in the treatment of refractory partial seizures
Conditions Studied
Interventions
- DRUG Placebo
- DRUG 800 mg QD Eslicarbazepine acetate
- DRUG 1200 mg QD Eslicarbazepine acetate
Study Locations (20)
California
- Kern County Neurological Medical Group, INC. - Bakersfield
- Neuro-Pain Medical Center, Inc. - Fresno
- Loma Linda University - Loma Linda
- Collaborative Neuroscience Network, INC - Long Beach
- Viking Clinical Research Center - Murrieta
- Bright Minds Institute - San Francisco
- Milestone Clinical Research - San Jose
- Neurosearch II, Inc. - Ventura
Arizona
- 21st Century Neurology - Division of Xenoscience, Inc. - Phoenix
- Barrow Neurological Institute / St. Joseph's Hospital and Medical Center - Phoenix
- Phoenix Neurological Associates/Clinical Research Advantage - Phoenix
- ANI Research, PC - Sun City
- University of Arizona Health Sciences Center - Tucson
Alabama
- University of South Alabama Department of Neurology - Mobile
- Neurology Clinic, P.C. - Northport
Arkansas
- Arkansas Neurology - Conway
- Clinical Trials Inc. - Little Rock
Colorado
- University of Colorado Health Sciences - Aurora
- Denver Health - Denver
Florida
- Bradenton Research Center - Bradenton
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 653 participants |
| Start Date | 2008-12-02 |
| Est. Completion | 2012-01-12 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00988429
The ClinicalTrials.gov registry entry for NCT00988429 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 653 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 427-participant average among 7 other Partial Epilepsy trials with a reported enrollment target (53% higher). The listed sponsor is Bial - Portela C S.A., which has 4 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Partial Epilepsy appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT00988429 reports 20 study locations spanning 6 distinct geographic areas - top geographies include California, Arizona, Alabama.
Frequently Asked Questions
What is clinical trial NCT00988429 about?
NCT00988429 is a clinical study titled "Efficacy and Safety of Eslicarbazepine Acetate (BIA 2-093) as Adjunctive Therapy for Refractory Partial Seizures". The purpose of this study is to determine whether Eslicarbazepine acetate (BIA 2-093) is an effective adjunct therapy in the treatment of refractory partial seizures
What is the current status of trial NCT00988429?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 653 participants. The study started on 2008-12-02. Estimated completion is 2012-01-12.
What conditions does trial NCT00988429 study?
This clinical trial studies the following conditions: Partial Epilepsy.
What interventions are being tested in trial NCT00988429?
The interventions under investigation include: Placebo (DRUG), 800 mg QD Eslicarbazepine acetate (DRUG), 1200 mg QD Eslicarbazepine acetate (DRUG).
Who is sponsoring clinical trial NCT00988429?
This trial is sponsored by Bial - Portela C S.A., which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00988429 being conducted?
This trial has 20 study locations across Alabama, Arizona, Arkansas, California, Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Partial Epilepsy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Safety and Efficacy Study of Cenobamate in Pediatric Subjects 2-17 Years of Age With Partial-onset (Focal) Seizures
RECRUITING · Phase 3
-
Safety and Pharmacokinetic Study of YKP3089 as Adjunctive Therapy in Subjects With Partial Onset Seizures
COMPLETED · Phase 3
-
Surgery as a Treatment for Medically Intractable Epilepsy
RECRUITING
-
Investigating Epilepsy: Screening and Evaluation
RECRUITING
-
Metabolic Abnormalities in Children With Epilepsy
COMPLETED
-
Transcranial Magnetic Stimulation for the Treatment of Poorly Controlled Partial Epilepsy
COMPLETED
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.